Name;Gene(s);Gene_change;Aminoacid_change;Protein_change;Condition(s);Clinical significance (Last reviewed);Review status;Accession;GRCh37Chromosome;GRCh37Location;GRCh38Chromosome;GRCh38Location;VariationID;AlleleID(s);dbSNP ID;Canonical SPDI
NM_002755.3(MAP2K1):c.332T>A (p.Ile111Asn);MAP2K1;c.332T>A ;(p.Ile111Asn);I111N;Rasopathy|Neoplasm;Pathogenic(Last reviewed: Oct 28, 2019);criteria provided, single submitter;VCV000376194;15;66729124;15;66436786;376194;363073;rs1057519730;NC_000015.10:66436785:T:A
NM_002755.3(MAP2K1):c.370C>T (p.Pro124Ser);MAP2K1;c.370C>T;(p.Pro124Ser);P124S;Malignant melanoma of skin|Noonan syndrome|Malignant neoplasm of body of uterus|Cardiofaciocutaneous syndrome 3|Rasopathy|Neoplasm of the large intestine|Transitional cell carcinoma of the bladder|not provided|Melanoma;Pathogenic(Last reviewed: Jul 2, 2020);reviewed by expert panel;VCV000375981;15;66729162;15;66436824;375981;362860;rs1057519732;NC_000015.10:66436823:C:T
NM_002755.3(MAP2K1):c.323G>T (p.Arg108Leu);MAP2K1;c.323G>T;(p.Arg108Leu);R108L;Cardiofaciocutaneous syndrome 3|Noonan syndrome 1|Cardiofaciocutaneous syndrome 3|not provided|Rasopathy;Pathogenic(Last reviewed: Jun 25, 2020);reviewed by expert panel;VCV000280446;15;66729115;15;66436777;280446;264875;rs727504819;NC_000015.10:66436776:G:T
NM_002755.4(MAP2K1):c.364A>G (p.Asn122Asp);MAP2K1;c.364A>G;(p.Asn122Asp);N122D;Rasopathy|Noonan syndrome|Noonan syndrome 1|Cardiofaciocutaneous syndrome 3;Pathogenic(Last reviewed: Mar 16, 2020);reviewed by expert panel;VCV000228273;15;66729156;15;66436818;228273;230599;rs876657651;NC_000015.10:66436817:A:G
NM_002755.4(MAP2K1):c.199G>A (p.Asp67Asn);MAP2K1;c.199G>A;(p.Asp67Asn);D67N;MAP2K1-related RASopathy|Cardio-facio-cutaneous syndrome|Cardio-facio-cutaneous syndrome|Noonan syndrome|not provided|Rasopathy|Non-small cell lung cancer|Cardiofaciocutaneous syndrome 3|Melanoma|Autism spectrum disorder;Pathogenic(Last reviewed: May 9, 2017);reviewed by expert panel;VCV000040781;15;66727483;15;66435145;40781;49251;rs727504317;NC_000015.10:66435144:G:A
NM_002755.3(MAP2K1):c.383_384delinsTT (p.Gly128Val);MAP2K1;c.383_384delinsTT;(p.Gly128Val);G128V;Rasopathy;Pathogenic(Last reviewed: Nov 4, 2012);criteria provided, single submitter;VCV000040745;15;66729175 - 66729176;15;66436837 - 66436838;40745;49215;rs730880508;NC_000015.10:66436836:GC:TT
NM_002755.4(MAP2K1):c.383G>T (p.Gly128Val);MAP2K1;c.383G>T;(p.Gly128Val);G128V;Rasopathy|Cardiofaciocutaneous syndrome 3|not provided|Cardio-facio-cutaneous syndrome;Pathogenic/Likely pathogenic(Last reviewed: Jul 24, 2019);criteria provided, multiple submitters, no conflicts;VCV000013352;15;66729175;15;66436837;13352;28391;rs121908596;NC_000015.10:66436836:G:T
NM_002755.4(MAP2K1):c.389A>G (p.Tyr130Cys);MAP2K1;c.389A>G;(p.Tyr130Cys);Y130C;Hypertrophic cardiomyopathy|Global developmental delay|Proportionate short stature|Abnormality of the sternum|Failure to thrive|Seizures|Cortical dysplasia|Cardiofaciocutaneous syndrome 3|Noonan syndrome 1|not provided|Cardiofaciocutaneous syndrome 3|Inborn genetic diseases|Rasopathy|Cardio-facio-cutaneous syndrome;Pathogenic(Last reviewed: May 9, 2017);reviewed by expert panel;VCV000013351;15;66729181;15;66436843;13351;28390;rs121908595;NC_000015.10:66436842:A:G
NM_002755.3(MAP2K1):c.158T>C (p.Phe53Ser);MAP2K1;c.158T>C;(p.Phe53Ser);F53S;Cardiofaciocutaneous syndrome 3|Cardio-facio-cutaneous syndrome|not provided;Pathogenic(Last reviewed: May 9, 2017);reviewed by expert panel;VCV000013350;15;66727442;15;66435104;13350;28389;rs121908594;NC_000015.10:66435103:T:C
NM_030662.3(MAP2K2):c.171T>A (p.Phe57Leu);MAP2K2;c.171T>A;(p.Phe57Leu);F57L;Rasopathy;Pathogenic(Last reviewed: Dec 7, 2018);criteria provided, single submitter;VCV000578970;19;4117549;19;4117551;578970;574980;rs1057519910;NC_000019.10:4117550:A:T
NM_030662.4(MAP2K2):c.401A>G (p.Tyr134Cys);MAP2K2;c.401A>G;(p.Tyr134Cys);Y134C;Cardio-facio-cutaneous syndrome|Noonan syndrome|Rasopathy|not provided|Cardio-facio-cutaneous syndrome;Pathogenic(Last reviewed: May 9, 2017);reviewed by expert panel;VCV000177868;19;4110556;19;4110558;177868;176031;rs727504370;NC_000019.10:4110557:T:C
NM_030662.3(MAP2K2):c.181A>G (p.Lys61Glu);MAP2K2;c.181A>G;(p.Lys61Glu);K61E;not provided|Rasopathy|Cardiofaciocutaneous syndrome 1;Pathogenic/Likely pathogenic(Last reviewed: Jul 16, 2019);criteria provided, multiple submitters, no conflicts;VCV000040769;19;4117539;19;4117541;40769;49239;rs730880517;NC_000019.10:4117540:T:C
NM_030662.3(MAP2K2):c.383C>A (p.Pro128Gln);MAP2K2;c.383C>A;(p.Pro128Gln);;not provided|Cardiofaciocutaneous syndrome 4|Cardio-facio-cutaneous syndrome;Pathogenic(Last reviewed: May 9, 2017);reviewed by expert panel;VCV000008275;19;4110574;19;4110576;8275;23314;rs267607230;NC_000019.10:4110575:G:T
NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val);MAP2K2;c.169T>G;(p.Phe57Val);F57V;Adenocarcinoma of stomach|Cardiofaciocutaneous syndrome 4|Squamous cell carcinoma of the head and neck|Cardio-facio-cutaneous syndrome|Pancreatic adenocarcinoma|Malignant melanoma of skin;Pathogenic(Last reviewed: May 9, 2017);reviewed by expert panel;VCV000008273;19;4117551;19;4117553;8273;23312;rs121434498;NC_000019.10:4117552:A:C
NM_030662.3(MAP2K2):c.170T>G (p.Phe57Cys);MAP2K2;c.170T>G;(p.Phe57Cys);;not provided|Cardiofaciocutaneous syndrome 4|Cardio-facio-cutaneous syndrome;Pathogenic(Last reviewed: May 9, 2017);reviewed by expert panel;VCV000008272;19;4117550;19;4117552;8272;23311;rs121434497;NC_000019.10:4117551:A:C
